16Apr 2024
Roche's STARGLO Study Shows Improved Survival with Columvi Combination Therapy for DLBCL Patients

Roche's STARGLO Study Shows Improved Survival with Columvi Combination Therapy for DLBCL Patients

Roche announced that the Phase III STARGLO study met its primary endpoint by demonstrating a statistically significant improvement in overall survival for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study revealed that patients treated with Columvi® (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx) lived longer compared to those treated with MabThera®/Rituxan® (rituximab) and GemOx. Safety data indicated consistency with known profiles of individual medicines. The findings will be submitted to health authorities and presented at an upcoming medical conference.

  • #family health

Like

Save

Share